Feng Xu summarises research showing that the pathophysiological features of idiopathic pulmonary fibrosis are present before the time that symptoms usually appear, which could represent a window of opportunity to prevent disease progression (4:42).
Funding for independent interviews at ATS 2019 was provided by F.Hoffmann-La Roche Ltd, Basel, Switzerland.